全球重组疫苗市场规模、份额、成长分析，按最终用户（儿童和成人）、配销通路（医院和疫苗接种中心）- 2024-2031 年行业预测

Global Recombinant Vaccines Market Size, Share, Growth Analysis, By End user(Pediatric and Adult), By Distribution channel(Hospitals and Vaccination centers) - Industry Forecast 2024-2031

出版日期: 2024年03月17日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球重组疫苗市场规模为90.2亿美元，预计将从2023年的100.5亿美元成长到2031年的238.3亿美元，预测期间（2024-2031年）复合年增长率为11.40%。

过去，早期的疫苗严重依赖将个体暴露于减弱或灭活的病原体的方法。然而，随着基因工程、基因组学和重组 DNA 技术的出现，疫苗开发的格局发生了深刻的转变。这些创新方法催生了现已上市的新疫苗。与传统方法不同，这些疫苗是在受控实验室环境中製作的，利用基因筛检技术来减轻与传染病相关的风险。这不仅提高了疫苗的功效，也高度重视疫苗接种过程中的安全性。基因工程和疫苗开发的融合标誌着一项重大进步，使免疫接种方法更加精确和有针对性。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 欧洲其他地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 拉丁美洲其他地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- MEA 的其余部分

竞争格局

前 5 名玩家比较
2021 年关键参与者的市场定位
主要市场参与者所采取的策略
最佳制胜策略
近期市集活动
主要公司市占率（%），2021年

主要公司简介

AstraZeneca Plc.
Dynavax Technologies Corporation
Emergent BioSolutions Inc.
GlaxoSmithKline Plc.
Johnson & Johnson, Merck & Co. Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Serum Institute of India Pvt. Ltd.

简介目录

Product Code: SQMIG35A2767

Global Recombinant Vaccines Market size was valued at USD 9.02 Billion in 2022 and is poised to grow from USD 10.05 Billion in 2023 to USD 23.83 Billion by 2031, at a CAGR of 11.40% during the forecast period (2024-2031).

In the past, early vaccines heavily relied on methods that involved exposing individuals to weakened or deactivated pathogens. However, with the emergence of genetic engineering, genomics, and recombinant DNA technologies, the landscape of vaccine development has undergone a profound transformation. These innovative approaches have led to the creation of new vaccines now available in the market. Unlike traditional methods, these vaccines are crafted in controlled laboratory environments, leveraging genetic screening techniques to mitigate the risks associated with infectious diseases. This not only enhances vaccine efficacy but also places a paramount emphasis on safety during the vaccination process. The fusion of genetic engineering and vaccine development marks a significant advancement, enabling a more precise and targeted approach to immunization.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Recombinant Vaccines Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Recombinant Vaccines Market Segmental Analysis

On the basis of indication, the market is classified into human papillomavirus, meningococcal and others. On the basis of end user, the market is bifurcated into pediatric and adult. On the basis of distribution channel, the market is classified into hospitals and vaccination centers. Region wise, the market is studied across North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa.

Drivers of the Global Recombinant Vaccines Market

A key factor driving market growth is the widespread use of recombinant properties, which significantly improve the effectiveness and safety of vaccines administered to patients. The inherent advantages of this technology enable rapid and large-scale vaccine production, reducing the risk of supply shortages. Additionally, these vaccines lack infectious viral particles, making them safe for individuals with compromised immune systems. The significant benefits of recombinant vaccines have prompted manufacturers to prioritize the development of innovative products targeting viral diseases. This effort involves harnessing advanced DNA technology, genomics, and other cutting-edge biotechnological techniques, collectively contributing to the development of more effective and safer vaccines.

Restraints in the Global Recombinant Vaccines Market

Despite the increased incidence of chronic and infectious diseases, the widespread uptake of vaccines is hindered by several factors, notably the exorbitant cost per dose. Despite the diligent efforts of international organizations in distributing millions of doses worldwide, the prohibitive expense of vaccination remains a significant obstacle for numerous populations. Despite concerted endeavors to ensure global coverage, certain regions still struggle with vaccine accessibility due to the enduring issue of high costs.

Market Trends of the Global Recombinant Vaccines Market

The rising prevalence of infectious diseases globally has sparked a critical need for efficient vaccines. This necessity is heightened by the heightened vulnerability of elderly and pediatric populations to severe illnesses, emphasizing the urgent requirement for swift vaccination initiatives on a global scale. Organizations like UNICEF and PAHO have been pivotal in distributing millions of vaccine doses to nations confronting urgent requirements, bolstering efforts to halt the spread of various diseases. Their effective procurement strategies have significantly curbed disease transmission and fortified communities against these health hazards.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Recombinant Vaccines Market by End user

Market Overview
Pediatric and Adult

Global Recombinant Vaccines Market by Distribution channel

Market Overview
Hospitals and Vaccination centers

Global Recombinant Vaccines Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

AstraZeneca Plc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dynavax Technologies Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline Plc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson, Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novavax, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Serum Institute of India Pvt. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments